SKINFUSION® TECHNOLOGY

Purposefully designed for her

Twirla® is for use in women of reproductive potential with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Consider Twirla's reduced effectiveness in women with a BMI ≥25 to <30 kg/m2 before prescribing.

Twirla is developed with Skinfusion, designed to promote drug administration and wearability.

DESIGNED WITH A 5-LAYER MATRIX
Not actual size. For illustrative purposes only. Select any of the Five-Layer system to learn more.
  • SOFT and FLEXIBLE
  • Less than 1 MM THIN
  • MADE UP OF 5 DISTINCT LAYERS for focused drug delivery and to help maintain adhesion

IMPORTANT SAFETY INFORMATION

+

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥30 kg/m2

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke.

Contraindicated in Women with a BMI ≥30 kg/m2

TWIRLA is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).